Search This Blog

Monday, June 1, 2026

AIM completes final patient enrollment ahead of schedule in Phase 2 in metastatic pancreatic cancer

 

AIM ImmunoTech completes final patient enrollment ahead of schedule in Phase 2 DURIPANC Ampligen trial in metastatic pancreatic cancer

  • Study remains on track for December 2026 primary endpoint evaluation following completion of final patient enrollment.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)